Michael Veve, PharmD, MPH

Michael Veve, PharmD, MPH

Assistant Professor (Clinical)




Pharmacy Practice

Research website


Michael Veve, PharmD, MPH

Degrees and Certifications

  • 2020 - Master of Public Health, Wayne State University School of Medicine, Detroit, MI
  • 2017 - Fellowship in Infectious Diseases Outcomes Research, Henry Ford Hospital/Wayne State University, Detroit, MI
  • 2015 - Pharmacy Practice Residency, Henry Ford Hospital, Detroit, MI
  • 2014 - Doctor of Pharmacy, Albany College of Pharmacy and Health Sciences, Albany, NY

Positions and Employment

  • 2020-Present - Clinical Assistant Professor, Wayne State University, College of Pharmacy, Detroit, MI
  • 2020-Present - Clinical Pharmacy Specialist, Infectious Diseases, Henry Ford Health System, Detroit, MI
  • 2017–2020- Clinical Assistant Professor, University of Tennessee Health Science Center, College of Pharmacy, Knoxville, TN

Awards and Honors

  • 2019 - Professor of the Year, 2018-2019, University of Tennessee Health Science Center College of Pharmacy

Professional Memberships

  • 2020 – 2022: American Public Health Association
  • 2018 – 2020: Tennessee Department of Health, Multi-Disciplinary Advisory Group on Healthcare Associated Infections
  • 2018 – 2020: Infectious Diseases Educator Network
  • 2018 – 2020: Tennessee Pharmacists Association
  • 2017 – Present: American Association of Colleges of Pharmacy
  • 2017 – 2019: The Society for Healthcare Epidemiology of America
  • 2016 – 2017: Infectious Diseases Society of America
  • 2015 – Present: Making a Difference in Infectious Diseases (MAD-ID) Research Network
  • 2015 – Present: Society of Infectious Diseases Pharmacists, Associate member
  • 2014 – 2020: American College of Clinical Pharmacy
  • 2014 – 2017: American Society for Microbiology
  • 2014 – 2017: Michigan Society of Health-System Pharmacists
  • 2013 – 2016: American Society of Health-System Pharmacists
  • 2009 – 2014: Northeastern New York Society of Hospital Pharmacists

Areas of Expertise

  • Antimicrobial stewardship
  • Public Health practice

Primary Research Interest

  • Implementation and assessment of novel antimicrobial stewardship interventions
  • Epidemilogy and outcomes of multi-drug resistant pathogens
  • Antimicrobial optimization in specialized patient populations
  • Prevention and treatment optimization of infections due to injection-drug use 

Recent Publications

Chapters Published

  • Veve MP. Chapter-33. Infectious Diseases. In: Chyka PA, Franks AS, Waddell JA, Boucher BA, eds. The APhA Complete Review for Pharmacy, 13th ed. Washington, DC: American Pharmacists Association. 2022.
  • Veve MP. Chapter 34: Anti-infective agents. In: Chyka PA, Franks AS, Waddell JA, Boucher BA, eds. The APhA Complete Review for Pharmacy, 13th ed. Washington, DC: American Pharmacists Association. 2022.


  • Mercuro NJ and Veve MP. Evaluating and reporting antimicrobial-related harms. Infectious Diseases Self-Assessment Program (IDSAP). American College of Clinical Pharmacy. 2022.
  • Veve MP and Athans V. Chapter 31 Vaccines. In: Ray SD, editor. Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Vol 41; Elsevier; 2019.
  • Veve MP and Athans V. Interactive Case: Antimicrobial stewardship in critical care. Critical Case. Critical Care Self-Assessment Program (CCSAP). American College of Clinical Pharmacy. 2019.
  • Veve MP and Athans V. Chapter 31 Vaccines. In: Ray SD, editor. Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Vol 40; Elsevier; 2018. p. 383-413.

Refereed Journals

  • Ho TA, Patterson KM, Gadgeel SM, Kenney RM, Veve MP. Cancer is chronic but antimicrobial stewardship is iconic: A retrospective cohort of optimal antibiotic use in ambulatory oncology clinics. Antimicrobial Stewardship & Healthcare Epidemiology (2023), 1–5.
  • Vuong L, Kenney RM, Thomson JM, Faison DJ, Church BM, McCollom R, Gunaga S, Cahill MM, Slezak MA, Davis SL, Veve MP. Implementation of indication-based antibiotic order sentences improves antibiotic use in emergency departments. Am J Emerg Med. 2023 Mar 29;69:5-10.
  • de Oca JEM, Veve MP, Zervos MJ, Kenney RM. Aminopenicillins versus Nonaminopenicillins for Treatment of Enterococcal Lower Urinary Tract Infections. Int J Antimicrob Agents. 2023 Mar 31:106800.
  • Kunz Coyne AJ, El Ghali A, Lucas K, Witucki P, Rebold N, Holger DJ, Veve MP, Rybak MJ. High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production. Open Forum Infect Dis. 2023 Jan 25;10(3):ofad034.
  • Arena CJ, Kenney RM, Kendall RE, Tibbetts RJ, Veve MP. Respiratory culture nudge improves antibiotic prescribing for Moraxella catarrhalis and Haemophilus influenzae lower respiratory tract infections. Antimicrob Steward Healthc Epidemiol. 2023 Feb 2;3(1):e23.
  • Rebold N, Lagnf AM, Alosaimy S, Holger DJ, Witucki P, Mannino A, Dierker M, Lucas K, Kunz Coyne AJ, El Ghali A, Caniff KE, Veve MP, Rybak MJ. Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure. Microbiol Spectr. 2023 Feb 14;11(1):e0264722.
  • Alosaimy S, Morrisette T, Lagnf AM, Rojas LM, King MA, Pullinger BM, Hobbs ALV, Perkins NB, Veve MP, Bouchard J, Gore T, Jones B, Truong J, Andrade J, Huang G, Cosimi R, Kang-Birken SL, Molina KC, Biagi M, Pierce M, Scipione MR, Zhao JJ, Davis SL, Rybak MJ. Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiol Spectr. 2022 Oct 26;10(5):e0047922.
  • Holger DJ, Rebold NS, Alosaimy S, Morrisette T, Lagnf A, Belza AC, Coyne AJK, El Ghali A, Veve MP, Rybak MJ. Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively DrugResistant Pseudomonas aeruginosa Lower Respiratory Tract Infections. Infect Dis Ther. 2022 Oct;11(5):1965-1980.
  • Alosaimy S, Lagnf AM, Hobbs ALV, Mubarez M, Kufel WD, Morrisette T, Polisetty RS, Li D, Veve MP, Simon SP, Truong J, Finch N, Venugopalan V, Rico M, Amaya L, Yost C, Cubillos A, Chandler E, Patch M, Smith IMK, Biagi M, Wrin J, Moore WJ, Molina KC, Rebold N, Holger D, Kunz Coyne AJ, Jorgensen SCJ, Witucki P, Tran NN, Davis SL, Sakoulas G, Rybak MJ. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam. Clin Infect Dis. 2023 Feb 8;76(3):e1444-e1455.
  • Veve MP, Mercuro NJ, Sangiovanni RJ, Santarossa M, Patel N. Prevalence and Predictors of Pseudomonas aeruginosa Among Hospitalized Patients With Diabetic Foot Infections. Open Forum Infect Dis. 2022 Jun 17;9(7):ofac297.
  • Morrisette T, Alosaimy S, Lagnf AM, Frens JJ, Webb AJ, Veve MP, Stevens R, Bouchard J, Gore TW, Ansari I, Rybak MJ. Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens. Infect Dis Ther. 2022 Aug;11(4):1715-1723.
  • Walton MN, Hamilton LA, Kennedy S, Veve MP, Rowe AS. Incidence of infection and antimicrobial prophylaxis duration for external ventricular drains and intracranial pressure monitors. Surg Infect (Larchmt). 2022 Feb 8. doi: 10.1089/sur.2021.310. Epub ahead of
  • Zasowski EJ, TrinhTD, Claeys KC, LagnfAM, Bhatia S, KlinkerKP, Veve MP, Estrada SJ, JohnsS, Sawyer AJ, Huang V, LaFrance B, Levine DP, Kaye KS, Davis SL, Rybak MJ. Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillinresistant Staphylococcus aureus bloodstream infection. Open Forum Infect Dis. 2021 Dec 23;9(3):ofab606.
  • Kelly MC, Yeager SD, Shorman MA, Wright LR, Veve MP. Incidence and predictors of Gram-negative infections in hospitalized people who inject drugs with injection drug useattributable infections. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0092521.
  • Cernasev A, Veve MP, Summers NA, Hohmeier KC, Kumar S. Importance of PharmacistPatient Relationships in People Living with HIV and Opioid Use Disorder. Exploratory Research in Clinical and Social Pharmacy. 2021. 3. 100052. 10.1016/j.rcsop.2021.100052.
  • Alosaimy S, Lagnf AM, Morrisette T, Scipione MR, Zhao JJ, Jorgensen SCJ, Mynatt R, Carlson TJ, Jo J, Garey KW, Allen D, DeRonde K, Vega A, Abbo LM, Venugopalan V, Athans V, Saw S, Claeys KC, Miller M, Veve MP, Kufel WD, Amaya L, Yost C, Ortwine J, Davis SL, Rybak MJ. Real-world multi-center experience with meropenem-vaborbactam for multidrug-resistant Gram-negative bacterial infections. Open Forum Infect Dis. 2021 Jul 14;8(8):ofab371. doi: 10.1093/ofid/ofab371.
  • Cernasev A, Frederick KD, Hall EA, Veve MP, Hohmeier KC. “Don’t label them as addicts!” Student pharmacists’ views on the stigma associated with opioid use disorder. Innov Pharm. 2021 Jun 10;12(2):10.24926/iip.v12i2.3388.
  • Yeager SD, Oliver JE, Shorman MA, Wright LR, Veve MP. Comparison of linezolid stepdown therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections. Accepted for publication at Inter J Antimicrob Agents. 2021. In
  • Cernasev A, Kodidela S, Veve MP, Cory TJ, Jasmin H, Kumar S. A narrative systematic literature review: a focus on qualitative studies on HIV and medication assisted therapy in the United States. Accepted for publication at Pharmacy. 2021. In press.
  • Morrisette T, Alosaimy S, Philley JV, Sigler C, Howard C, Webb AJ, Veve MP, Barger ML, Bouchard J, Gore TW, Lagnf AM, Ansari I, Mejia-Chew C, Cohen KA, Rybak MJ. Preliminary, real-world, multi-center experience with omadacycline for Mycobacterium
    abscessus infections. Open Forum Infect Dis. 2021. Epub ahead of print.
  • Cernasev A, Veve MP, Talbott T, Hall EA, Hohmeier KC. Student pharmacists’ perceptions and stigma surrounding naloxone use in patients with opioid use disorder: a mixed methods evaluation. Pharmacy (Basel). 2020 Nov;8, 205.
  • Veve MP, Akhtar Y, McKeown PP, Morelli MK, Shorman MA. Percutaneous mechanical aspiration vs valve surgery for tricuspid-valve endocarditis in people who inject drugs. Ann Thorac Surg. 2020 Oct 20:S0003-4975(20)31720-3. Epub ahead of print
  • Morelli MK, Veve MP, Lorson W, Shorman MA. Candida spp. infective endocarditis: characteristics and outcomes of twenty cases with a focus on injection drug use as a predisposing risk factor. Mycoses. 2020 Oct 18. doi: 10.1111/myc.13200. Epub ahead of print.
  • Veve MP, Patel N, Smith ZA, Yeager SD, Wright LR, Shorman MA. Comparison of dalbavancin to standard of care for outpatient treatment of invasive Gram-positive infections. Inter J Antimicrob Agents. 2020 Oct 23:106210. Epub ahead of print.
  • Cooksey GE, Moye RA, Epps JL, Patel N, Shorman MA, Veve MP. Impact of a plan of care protocol on patient outcomes in people who inject drugs with infective endocarditis. J Infect Dis. 2020 Sep 2;222(Supplement_5):S506-S512.
  • Cernasev A, Veve MP, Cory TJ, Summers NA, Miller M, Kodidela S, Kumar S. Opioid use disorders in people living with HIV/AIDS: a review of implications for patient outcomes, drug interactions, and neurocognitive disorders. Pharmacy (Basel). 2020 Sep 11;8(3):E168.
  • Hall E, Cernasev A, Nastritdinova U, Veve MP, Hohmeier K. Student pharmacist perceptions of opioid use and stigma. Pharmacy (Basel). 2020 Aug 14;8(3):E144.
  • Mercuro NJ, Veve MP. Clinical utility of lefamulin: if not now, when? Curr Infect Dis Rep. 2020;22(9):25.
  • Morelli MK, Veve MP, Shorman MA. Maternal bacteremia caused by Staphylococcus aureus with a focus on infective endocarditis. Open Forum Infect Dis. 2020 Jun 19;7(8):ofaa239
  • Veve MP, McCurry ED, Cooksey GE, Shorman MA. Epidemiology and outcomes of NonHACEK infective endocarditis in the southeast United States. PLOS One. 2020 Mar 10;15(3):e0230199.
  • Alosaimy S, Jorgensen SCJ, Lagnf Am, Melvin S, Mynatt RP, Carlson TJ, Garey KW, Allen D, Venugopalan V, Veve M, Athans V, Saw S, Yost CN, Davis SL, Rybak MJ. Real-world multicenter analysis of clinical outcomes and safety of meropenemvaborbactam in patients treated for serious Gram-negative bacterial infections. Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051
  • Jorgensen SCJ, Murray KP, Lagnf AM, Melvin S, Bhatia S, Shamim MD, Smith JR, Brade KD, Simon S, Nagel J, Williams K, Ortwine J, Veve MP, Truong J, Davis SL, Rybak MJ. A multicenter evaluation of vancomycin-associated acute kidney injury in hospitalized
    patients with acute bacterial skin and skin structure infections. Infect Dis Ther. 2020 Mar;9(1):89-106.
  • Lorson W, Veve MP, Heidel E, Shorman MA. The role of troponin as a predictor of inpatient mortality in infective endocarditis. BMC Infect Dis. 2020 Jan 8;20(1):24.
  • Pogue JM, Kaye KS, Veve MP, Gerlach A, Patel TS, Davis SL, Dhar S, Puzniak L, File TM, Bonomo RA, Perez F. Real world treatment of multi-drug resistant (MDR) or extensively-drug resistant (XDR) P. aeruginosa infections with ceftolozane/tazobactam (C/T) versus a polymyxin or aminoglycoside (Poly/AG) based regimen: a multicenter comparative effectiveness study. Clin Infect Dis. 2020;71(2):304-310.

Courses taught by Michael Veve, PharmD, MPH

Winter Term 2024

Spring-Summer Term 2023

Winter Term 2023

Winter Term 2022

← Return to listing